Surgical treatment of small bowel cancer: A 20-year single institution experience

Hiromichi Ito, Alexander Perez, David C. Brooks, Robert T. Osteen, Michael J. Zinner, Francis D. Moore, Stanley W. Ashley, Edward E. Whang

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

Small bowel malignancies are rare. The aims of this study were to evaluate the outcomes associated with surgical therapy for small bowel cancers and to define prognostic factors. The medical records of 96 consecutive patients with primary small bowel cancer (excluding lymphoma) treated at our institution over a 20 year period were reviewed. Survival was analyzed using the Kaplan-Meier method (mean follow-up period 57 months). Mean patient age was 56 years, and 58% of patients were male. Sixty percent of patients had an adenocarcinoma, 21% had a sarcoma, and 19% had a carcinoid tumor. The percentages of patients who underwent complete (curative) resection were 51%, 90%, and 50% for those with adenocarcinoma, sarcoma, and carcinoid tumor, respectively. For patients with adenocarcinoma who underwent curative resection, tumor (T) and node (N) stages were significant prognostic factors predicting overall survival. For patients with sarcomas who underwent curative resection, tumor grade was a significant prognostic factor predicting overall survival. The prognosis for patients with small intestinal carcinoid tumors is uniformly favorable. The prognosis for patients with sarcomas and adenocarcinomas is generally poor, although long-term survival is achieved by patients with favorable prognostic factors.

Original languageEnglish (US)
Pages (from-to)925-930
Number of pages6
JournalJournal of Gastrointestinal Surgery
Volume7
Issue number7
DOIs
StatePublished - Nov 2003
Externally publishedYes

Keywords

  • Adenocarcinoma
  • Carcinoid tumor
  • Sarcoma
  • Small bowel cancer

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Surgical treatment of small bowel cancer: A 20-year single institution experience'. Together they form a unique fingerprint.

Cite this